.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Royalty Pharma cash on hand 2015–2026What is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
Royalty Pharma had 544.86M USD in cash and short-term investments on 30 September 2026, down 42.9% on a year before. At the end of fiscal year 2025 it had 637.50M USD.
Last updated 6 Nov 2026 · Next report 10 Feb 2027
Cash on hand
Growth
| Fiscal year | Period ending | Cash on hand | Growth | Total debt | Net cash |
|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 544.86M | -42.95% | 8.59B | -8.04B |
| FY2025 | 31 Dec 2025 | 637.50M | -64.00% | 8.95B | -8.31B |
| FY2024 | 31 Dec 2024 | 1.77B | +43.55% | 7.61B | -5.84B |
| FY2023 | 31 Dec 2023 | 1.23B | -49.18% | 6.14B | -4.90B |
| FY2022 | 31 Dec 2022 | 2.43B | -13.39% | 7.12B | -4.69B |
| FY2021 | 31 Dec 2021 | 2.80B | +5.82% | 7.10B | -4.29B |
| FY2020 | 31 Dec 2020 | 2.65B | +233.97% | 5.82B | -3.17B |
| FY2019 | 31 Dec 2019 | 793.21M | -66.76% | 6.24B | -5.44B |
| FY2018 | 31 Dec 2018 | 2.39B | +72.70% | 6.52B | -4.13B |
| FY2017 | 31 Dec 2017 | 1.38B | -17.48% | 6.80B | -5.42B |
| FY2016 | 31 Dec 2016 | 1.67B | -2.71% | 5.90B | -4.22B |
| FY2015 | 31 Dec 2015 | 1.72B | — | 5.99B | -4.27B |
| Quarter | Period ending | Cash on hand | Growth on a year before | Total debt | Net cash |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 544.86M | -42.95% | 8.59B | -8.04B |
| Q2 FY2026 | 30 Jun 2026 | 837.00M | -43.75% | 8.96B | -8.12B |
| Q1 FY2026 | 31 Mar 2026 | 608.30M | -66.51% | 8.96B | -8.35B |
| Q4 FY2025 | 31 Dec 2025 | 637.80M | -63.99% | 8.95B | -8.31B |
| Q3 FY2025 | 30 Sept 2025 | 955.04M | -45.87% | 8.97B | -8.01B |
| Q2 FY2025 | 30 Jun 2025 | 1.49B | -41.72% | 8.00B | -6.51B |
| Q1 FY2025 | 31 Mar 2025 | 1.82B | +18.53% | 7.62B | -5.80B |
| Q4 FY2024 | 31 Dec 2024 | 1.77B | +43.55% | 7.61B | -5.84B |
| Q3 FY2024 | 30 Sept 2024 | 1.76B | +4.78% | 7.61B | -5.84B |
| Q2 FY2024 | 30 Jun 2024 | 2.55B | -12.20% | 7.60B | -5.05B |
| Q1 FY2024 | 31 Mar 2024 | 1.53B | -40.79% | 6.14B | -4.61B |
| Q4 FY2023 | 31 Dec 2023 | 1.23B | -49.18% | 6.14B | -4.90B |
| Q3 FY2023 | 30 Sept 2023 | 1.68B | -24.04% | 6.13B | -4.45B |
| Q2 FY2023 | 30 Jun 2023 | 2.91B | -14.50% | 7.13B | -4.22B |
| Q1 FY2023 | 31 Mar 2023 | 2.59B | -11.10% | 7.12B | -4.53B |
| Q4 FY2022 | 31 Dec 2022 | 2.43B | -13.39% | 7.12B | -4.69B |
| Q3 FY2022 | 30 Sept 2022 | 2.22B | -17.69% | 7.11B | -4.89B |
| Q2 FY2022 | 30 Jun 2022 | 3.40B | +28.33% | 7.11B | -3.70B |
| Q1 FY2022 | 31 Mar 2022 | 2.91B | +22.87% | 7.10B | -4.19B |
| Q4 FY2021 | 31 Dec 2021 | 2.80B | +5.82% | 7.10B | -4.29B |
| Q3 FY2021 | 30 Sept 2021 | 2.69B | -1.44% | 7.09B | -4.40B |
| Q2 FY2021 | 30 Jun 2021 | 2.65B | -20.70% | 5.83B | -3.18B |
| Q1 FY2021 | 31 Mar 2021 | 2.37B | +39.69% | 5.82B | -3.45B |
| Q4 FY2020 | 31 Dec 2020 | 2.65B | +233.97% | 5.82B | -3.17B |
| Q3 FY2020 | 30 Sept 2020 | 2.73B | — | 5.81B | -3.08B |
| Q2 FY2020 | 30 Jun 2020 | 3.34B | — | 5.91B | -2.57B |
| Q1 FY2020 | 31 Mar 2020 | 1.70B | -12.72% | 5.96B | -4.26B |
| Q4 FY2019 | 31 Dec 2019 | 793.21M | — | 6.24B | -5.44B |
| Q1 FY2019 | 31 Mar 2019 | 1.94B | — | 0.00 | 1.94B |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet
Common questions about Royalty Pharma's cash
Source: Financial Modeling Prep